ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
China’s BeiGene delays US filing for rival to ImbruvicaBeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s Share XChina’s BeiGene delays US filing for rival to Imbruvicahttps://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/
